UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 2, 2017
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At August 7, 2017, 5,947,349,054 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended July 2, 2017 and July 3, 2016
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 2, 2017 and
July 3, 2016
Condensed Consolidated Balance Sheets as of July 2, 2017 and December 31, 2016
Condensed Consolidated Statements of Cash Flows for the six months ended July 2, 2017 and July 3, 2016
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
43
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
44
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
103
Item 4.
Controls and Procedures
103
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
104
Item 1A.
Risk Factors
104
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
105
Item 3.
Defaults Upon Senior Securities
105
Item 4.
Mine Safety Disclosures
105
Item 5.
Other Information
105
Item 6.
Exhibits
106
Signature
107
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2016 Financial Report
Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016
2016 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2016
AAV
Adeno-Associated Virus
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Allergan
Allergan plc
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Anacor
Anacor Pharmaceuticals, Inc.
Astellas
Astellas Pharma U.S., Inc.
ASU
Accounting Standards Update
ATM-AVI
aztreonam-avibactam
Bamboo
Bamboo Therapeutics, Inc.
BMS
Bristol-Myers Squibb Company
CDC
U.S. Centers for Disease Control and Prevention
Cellectis
Cellectis SA
Citibank
Citibank N.A.
Developed Markets
U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand
EEA
European Economic Area
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey
EPS
earnings per share
EU
European Union
EURIBOR
Euro Interbank Offered Rate
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development
HER2-
human epidermal growth factor receptor 2-negative
HIS
Hospira Infusion Systems
Hisun
Zhejiang Hisun Pharmaceuticals Co., Ltd.
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
King
King Pharmaceuticals, Inc.
LDL
low density lipoprotein
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCO
Managed Care Organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation, Inc.
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
NDA
new drug application
NovaQuest
NovaQuest Co-Investment Fund V, L.P.
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PBM
Pharmacy Benefit Manager
Pharmacia
Pharmacia Corporation
PP&E
Property, plant & equipment
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended July 2, 2017
RCC
renal cell carcinoma
R&D
research and development
RPI
RPI Finance Trust
Sandoz
Sandoz, Inc., a division of Novartis AG
Sangamo
Sangamo Therapeutics, Inc.
SEC
U.S. Securities and Exchange Commission
SFJ
SFJ Pharmaceuticals Group
S&P
Standard and Poor s
Teuto
Laborat rio Teuto Brasileiro S.A.
U.K.
United Kingdom
U.S.
United States
ViiV
ViiV Healthcare Limited
WRD
Worldwide Research and Development
Zoetis
Zoetis Inc.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
July 2,
2017
July 3,
2016
July 2,
2017
July 3,
2016
Revenues
12,896
13,147
25,675
26,152
Costs and expenses:
Cost of sales(a)
2,663
3,174
5,134
6,026
Selling, informational and administrative expenses(a)
3,425
3,471
6,733
6,856
Research and development expenses(a)
1,780
1,748
3,487
3,478
Amortization of intangible assets
1,208
961
2,394
1,966
Restructuring charges and certain acquisition-related costs
70
316
228
457
Other (income)/deductions net
(66
1,068
(68
1,398
Income from continuing operations before provision for taxes on income
3,815
2,410
7,767
5,971
Provision for taxes on income(b)
739
347
1,560
861
Income from continuing operations(b)
3,077
2,062
6,207
5,110
Discontinued operations net of tax
Net income before allocation to noncontrolling interests(b)
3,078
2,063
6,208
5,111
Less: Net income attributable to noncontrolling interests
16
14
25
Net income attributable to Pfizer Inc.(b)
3,073
2,047
6,194
5,085
Earnings per common share basic(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.52
0.34
1.04
0.83
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.52
0.34
1.04
0.83
Earnings per common share diluted(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.51
0.33
1.02
0.82
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.51
0.33
1.02
0.82
Weighted-average shares basic
5,958
6,068
5,982
6,110
Weighted-average shares diluted
6,037
6,149
6,065
6,188
Cash dividends paid per common share
0.32
0.30
0.64
0.60
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
(b)
Amounts for the three and six months ended July 3, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies Adoption of New Accounting Standards.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
July 2,
2017
July 3,
2016
July 2,
2017
July 3,
2016
Net income before allocation to noncontrolling interests
3,078
2,063
6,208
5,111
Foreign currency translation adjustments, net
247
515
474
581
Reclassification adjustments(a)
111
112
358
515
586
581
Unrealized holding losses on derivative financial instruments, net
(90
(571
(99
(845
Reclassification adjustments for realized (gains)/losses(b)
(208
469
(449
130
(297
(102
(548
(714
Unrealized holding gains on available-for-sale securities, net
164
350
314
479
Reclassification adjustments for realized (gains)/losses(b)
(40
(226
97
(16
124
124
412
463
Benefit plans: actuarial gains/(losses), net
61
(19
62
(19
Reclassification adjustments related to amortization(c)
145
139
308
278
Reclassification adjustments related to settlements, net(c)
(1
22
51
48
Other
(80
(57
(35
(18
124
85
385
288
Benefit plans: prior service (costs)/credits and other, net
(2
87
(2
87
Reclassification adjustments related to amortization(c)
(46
(41
(91
(81
Reclassification adjustments related to curtailments, net(c)
(4
(11
(6
Other
(52
48
(104
Other comprehensive income, before tax
258
669
732
624
Tax provision/(benefit) on other comprehensive income(d)
(163
36
(138
(5
Other comprehensive income before allocation to noncontrolling interests
421
633
870
629
Comprehensive income before allocation to noncontrolling interests
3,499
2,696
7,078
5,740
Less: Comprehensive income attributable to noncontrolling interests
13
21
29
24
Comprehensive income attributable to Pfizer Inc.
3,486
2,676
7,049
5,715
(a)
The foreign currency translation adjustments reclassified into Other (income)/deductions net in the condensed consolidated statements of income primarily result from the agreement to sell our 40% ownership investment in Teuto. See Note 2D. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments.
(b)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income.
(c)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(d)
See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
July 2,
2017
December 31,
2016
(Unaudited)
Assets
Cash and cash equivalents
2,585
2,595
Short-term investments
11,748
15,255
Trade accounts receivable, less allowance for doubtful accounts: 2017 $579; 2016 $609
9,476
8,225
Inventories
7,584
6,783
Current tax assets
3,113
3,041
Other current assets
1,877
2,249
Assets held for sale
801
Total current assets
36,385
38,949
Long-term investments
7,008
7,116
Property, plant and equipment, less accumulated depreciation: 2017 $15,506; 2016 $14,807
13,386
13,318
Identifiable intangible assets, less accumulated amortization
51,348
52,648
Goodwill
55,014
54,449
Noncurrent deferred tax assets and other noncurrent tax assets
1,952
1,812
Other noncurrent assets
3,466
3,323
Total assets
168,558
171,615
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2017 $3,072; 2016 $4,225
9,514
10,688
Trade accounts payable
3,439
4,536
Dividends payable
1,904
1,944
Income taxes payable
552
437
Accrued compensation and related items
1,625
2,487
Other current liabilities
10,148
11,023
Total current liabilities
27,182
31,115
Long-term debt
34,191
31,398
Pension benefit obligations, net
5,371
6,406
Postretirement benefit obligations, net
1,705
1,766
Noncurrent deferred tax liabilities
30,879
30,753
Other taxes payable
4,096
4,000
Other noncurrent liabilities
6,440
6,337
Total liabilities
109,863
111,776
Commitments and Contingencies
Preferred stock
23
24
Common stock
463
461
Additional paid-in capital
83,373
82,685
Treasury stock
(89,416
(84,364
Retained earnings
74,107
71,774
Accumulated other comprehensive loss
(10,181
(11,036
Total Pfizer Inc. shareholders equity
58,368
59,544
Equity attributable to noncontrolling interests
326
296
Total equity
58,694
59,840
Total liabilities and equity
168,558
171,615
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(MILLIONS OF DOLLARS)
July 2,
2017
July 3,
2016
Operating Activities
Net income before allocation to noncontrolling interests
6,208
5,111
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
3,129
2,812
Asset write-offs and impairments
97
983
Loss on sale of HIS net assets
64
Deferred taxes from continuing operations
320
(10
Share-based compensation expense
388
387
Benefit plan contributions in excess of expense
(1,079
(857
Other adjustments, net
(433
170
Other changes in assets and liabilities, net of acquisitions and divestitures(a)
(3,853
(3,182
Net cash provided by operating activities
4,841
5,414
Investing Activities
Purchases of property, plant and equipment
(806
(702
Purchases of short-term investments
(2,394
(8,744
Proceeds from redemptions/sales of short-term investments
3,520
14,757
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less
3,424
(249
Purchases of long-term investments
(1,663
(3,126
Proceeds from redemptions/sales of long-term investments
1,539
2,427
Acquisitions of businesses, net of cash acquired
(1,000
(4,616
Acquisitions of intangible assets
(41
(96
Other investing activities, net
455
26
Net cash provided by/(used in) investing activities
3,034
(323
Financing Activities
Proceeds from short-term borrowings
4,799
2,307
Principal payments on short-term borrowings
(5,110
(2,291
Net proceeds from short-term borrowings with original maturities of three months or less
261
2,182
Proceeds from issuance of long-term debt
5,273
5,031
Principal payments on long-term debt
(4,473
(4,317
Purchases of common stock
(5,000
(5,000
Cash dividends paid
(3,855
(3,675
Proceeds from exercise of stock options
411
696
Other financing activities, net(a)
(228
(186
Net cash used in financing activities
(7,922
(5,253
Effect of exchange-rate changes on cash and cash equivalents
37
(68
Net decrease in cash and cash equivalents
(10
(230
Cash and cash equivalents, beginning
2,595
3,641
Cash and cash equivalents, end
2,585
3,411
Supplemental Cash Flow Information
Non-cash transactions:
Receipt of ICU Medical common stock(b)
428
Promissory note from ICU Medical(b)
75
Cash paid (received) during the period for:
Income taxes
1,121
1,111
Interest
881
903
Interest rate hedges
(226
(306
(a)
Amounts for the three and six months ended July 3, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.
(b)
In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock valued at $428 million and a promissory note in the amount of $75 million. For additional information, see Note 2B. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Sale of Hospira Infusion Systems Net Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.
We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.
The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 28, 2017 and May 29, 2016. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended July 2, 2017 and July 3, 2016.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2016 Form 10-K.
We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Beginning in the second quarter of 2016, we reorganized our operating segments to reflect that we manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH. For additional information, see Note 13 and Notes to Consolidated Financial Statements Note 18. Segment, Geographic and Other Revenue Information in Pfizer s 2016 Financial Report.
Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Our recent significant business development activities include:
On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in the condensed consolidated statement of income and EH s operating results through February 2, 2017 and, therefore, our financial results, and EH s operating results, for the second quarter of 2017 do not reflect any contribution from HIS global operations, while our financial results, and EH s operating results, for the second quarter of 2016 reflect three months of HIS global operations. Our financial results, and EH s operating results, for the first six months of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH s operating results, for the first six months of 2016 reflect six months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities.
On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, and EH s operating results, for the second quarter and first six months of 2017 reflect approximately three months and five months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.
On September 28, 2016, we acquired Medivation for $81.50 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH s operating results, and cash flows for the second quarter and first six months of 2017, but not for the second quarter and first six months of 2016.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
On June 24, 2016, we acquired Anacor for $99.25 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH s operating results, and cash flows for the second quarter and first six months of 2017, but for only five days in the second quarter and first six months of 2016.
For additional information, see Note 2 and Notes to Consolidated Financial Statements Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments in Pfizer s 2016 Financial Report.
B. Adoption of New Accounting Standards
In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the Provision for taxes on income, whereas excess tax benefits or deficiencies previously were recognized in Additional paid-in capital. The net tax benefit for the Company was $28 million for the second quarter of 2016 and $50 million for the first six months of 2016. Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit.
Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statements of cash flow. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, $51 million of cash outflows for the first six months of 2016 was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards included in our 2016 Financial Report.
We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.
We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. There was no material impact to our condensed consolidated financial statements from adopting this standard.
Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments